BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s revenue forecast decreases by 1% and EPS view is flat. For the later 2020’s, its total revenue estimates decrease by 10 to 12%, primarily due to lower sales from mRNA-1083 given the firm’s lower probability-of-success assumption and mRESVIA given its lower share assumption, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna’s Financial Outlook Dims: Revenue Projections and Diversification Challenges Lead to Sell Rating
- Moderna price target lowered to $28 from $39 at Bernstein
- RFK Jr. may reverse CDC’s Covid-19 recommendation for children, Politico says
- Cautious Outlook: Moderna’s Revenue and EPS Projections Lead to Hold Rating and Lowered Price Target
- VOO ETF News, 4/21/2025